Board of Directors

Ms. Giles joined the Milestone Pharmaceutical board of directors on October 1, 2020. She also serves on the board of directors of HCW Biologics, Inc. (NASDAQ: HCWB) since October 2021 and on Northwestern Memorial Foundation Board since 2013. She previously served as a member of the board of directors of GenMark Diagnostics, Inc. (NASDAQ: GNMK) from March 2015 until its acquisition by Roche Diagnostics in 2021 and of Durata Therapeutics, Inc., (NASDAQ: DRTX) from 2012 until its acquisition by Actavis(Allergan) plc in November 2014. Ms. Giles received a B.S. from Juniata College and has completed Executive Management Programs at Stanford University and the University of Chicago.

Ms. Giles has been the Managing Director and CEO of Giles & Associates Consultancy, Inc. (GAC) since 2000, and CEO of Optivara, Inc. since 2013. GAC is a privately held management consulting firm that specializes in global strategy development, market intelligence, and business development transactions for Life Science Companies and Academic Medical Centers. The firm advises corporate boards, CEOs, and executive leadership teams on strategic planning, R&D portfolio optimization, business plans and enterprise strategies.

From 1996-2000, Ms. Giles was Vice President of Strategy Development, at G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, internal consulting, marketing research, portfolio decision analysis and optimization, and M&A due diligence. Prior to Searle, she was a partner with Business Strategy Consultants, Portland Oregon, and a Director of Strategic Planning and held various leadership roles with Abbott Laboratories’ Diagnostic and Corporate Hospital Marketing Divisions.